CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10229|
|Brand Name||Opdivo and Yervoy|
|Generic Name||Nivolumab and Ipilimumab|
|Indication||Malignant Pleural Mesothelioma (MPM)|
|Funding Request||OPDIVO, in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma.|
|Pre Noc Submission||Yes|
|Manufacturer||Bristol-Myers Squibb Canada|
|Sponsor||Bristol-Myers Squibb Canada|
|Submission Date (Target Date)||October 29, 2020|
|Submission Type||New Indication|
|Stakeholder Input Deadline (target date based on target submission date) ‡||November 12, 2020|
|Check-point meeting (target date)|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.